The Pharmaceuticals Export Promotion Council of India (Pharmexcil) convened its 21st Annual General Meeting (AGM) on December 29, 2025, marking a defining moment in India’s pharmaceutical export journey. The AGM underscored the sector’s strategic pivot from volume-led growth to value-driven, innovation-oriented, and sustainability-anchored manufacturing.
Deliberations at the AGM highlighted the industry’s transition towards complex generics, speciality APIs, and advanced therapeutic platforms. Technical sessions and panel discussions reinforced the growing relevance of green and sustainable chemistry, with particular emphasis on flow chemistry and continuous manufacturing as enablers of consistent quality, regulatory compliance, and long-term competitiveness.
The year 2025 emerged as a milestone year for Indian pharma exports, with iPHEX at Bharat Mandapam standing out as a flagship achievement. The global exhibition successfully brought Indian exporters and international buyers onto a single platform, renewing global confidence in India’s pharmaceutical capabilities.
Reflecting on executional milestones and global engagement platforms, K Raja Bhanu, director general (DG), Pharmexcil, pointed to iPHEX as a tangible demonstration of India’s ability to translate manufacturing strength into business outcomes and enduring global partnerships. “iPHEX 2025 demonstrated the power of a well- orchestrated global platform—bringing Indian exporters and international buyers together to generate real business outcomes. Our focus remains on strengthening such platforms that convert India’s manufacturing strength into sustained export growth and long-term partnerships,” he said.
Read more here.
